Optimising outcomes in multiple myeloma

In these short videos, Dr Paula Rodríguez-Otero, Dr Joshua Richter and Dr Gabriele Buda share insights from the symposium at the EHA 2026 Congress on 'Optimising outcomes in multiple myeloma: Navigating resistance with innovative approaches’, sponsored by Menarini Stemline.  

,

Download the accompanying slides for further insights. 

Key topics include:  

• The evolving challenges in managing early relapsed multiple myeloma following standard frontline exposure 
• The rationale and trial data supporting XPO1 inhibition as an alternative mechanism to bypass treatment resistance 
• The role of XPO1 inhibition in upregulating BCMA expression and preserving T-cell fitness prior to T-cell redirecting therapies 
• Proactive adverse event management and dose-modification protocols for selinexor to optimise patient adherence and clinical outcomes

Clinical takeaways

• Utilise XPO1 inhibition strategically after frontline therapy failure 
• Implement treatment-free intervals and class switching to preserve T-cell fitness for future immunotherapies 
• Prioritise accessible 2ⁿᵈ line treatments for rapid disease control in early relapse, avoiding delays tied to real-world access limitations
• Employ proactive dose modifications and prophylaxis to manage adverse events, maximising tolerability and adherence to selinexor 

In these short videos, Dr Paula Rodríguez-Otero, Dr Joshua Richter, and Dr Gabriele Buda share insights from the symposium at the EHA 2026 Congress on 'Optimising outcomes in multiple myeloma: Navigating resistance with innovative approaches’, sponsored by Menarini Stemline.  

Download the accompanying slides for further insights. 

Key topics include:  

• The evolving challenges in managing early relapsed multiple myeloma following standard frontline exposure 
• The rationale and trial data supporting XPO1 inhibition as an alternative mechanism to bypass treatment resistance 
• The role of XPO1 inhibition in upregulating BCMA expression and preserving T-cell fitness prior to T-cell redirecting therapies 
• Proactive adverse event management and dose-modification protocols for selinexor to optimise patient adherence and clinical outcomes

Clinical takeaways

• Utilise XPO1 inhibition strategically after frontline therapy failure 
• Implement treatment-free intervals and class switching to preserve T-cell fitness for future immunotherapies 
• Prioritise accessible 2ⁿᵈ line treatments for rapid disease control in early relapse, avoiding delays tied to real-world access limitations
• Employ proactive dose modifications and prophylaxis to manage adverse events, maximising tolerability and adherence to selinexor 

In these short videos, Dr Paula Rodríguez-Otero, Dr Joshua Richter, and Dr Gabriele Buda share insights from the symposium at the EHA 2026 Congress on 'Optimising outcomes in multiple myeloma: Navigating resistance with innovative approaches’, sponsored by Menarini Stemline.  

Download the accompanying slides for further insights. 

Key topics include:  

• The evolving challenges in managing early relapsed multiple myeloma following standard frontline exposure 
• The rationale and trial data supporting XPO1 inhibition as an alternative mechanism to bypass treatment resistance 
• The role of XPO1 inhibition in upregulating BCMA expression and preserving T-cell fitness prior to T-cell redirecting therapies 
• Proactive adverse event management and dose-modification protocols for selinexor to optimise patient adherence and clinical outcomes

Clinical takeaways

• Utilise XPO1 inhibition strategically after frontline therapy failure 
• Implement treatment-free intervals and class switching to preserve T-cell fitness for future immunotherapies 
• Prioritise accessible 2ⁿᵈ line treatments for rapid disease control in early relapse, avoiding delays tied to real-world access limitations
• Employ proactive dose modifications and prophylaxis to manage adverse events, maximising tolerability and adherence to selinexor